Novo owner backs Swiss biotech company Asceneuron in $100 million round 

Swiss biotech company Asceneuron said Tuesday it has raised $100 million from investors including controlling shareholder Wegovy maker Novo Nordisk to fund clinical development of its drug to treat Alzheimer’s disease.

Compartir esta publicacion:

ENTRADAS POPULARES
SÍGANOS
Danos like en facebook
Síganos en Twitter
Suscríbase a nuestro canal
Tik Tok
TRANSMISIÓN EN VIVO